We continue to establish additional external partnerships with leading research institutes and pharmaceutical companies on technology and product licenses.
Collaboration with Huadong Medicine for the commercialization of CARsgen’s BCMA CAR T product Zevor-cel in mainland China. Huadong Medicine is granted the exclusive right to commercialize zevor-cel in mainland China.
CARsgen collaborates with Moderna to investigate CARsgen's investigational Claudin18.2 CAR T-cell product candidate (CT041) in combination with Moderna’s investigational Claudin18.2 mRNA cancer vaccine.
Licensing agreement with HK inno.N Corporation to develop and commercialize CAR T products, CT032 and CT053 (Zevor-cel), for the potential treatment of various cancers in the Republic of Korea.
We are committed to fostering strong collaborations with strategic partners, scientific and clinical researchers, and top medical centers to develop and advance cell therapies. With the vision of “Making Cancer Curable”, we have established well-integrated capabilities including target discovery, antibody development, clinical development, and commercial-scale manufacturing.
Working together with partners who share our vision provides the best opportunity to get much needed therapies to those suffering from hematologic malignancies and solid tumors. We know that patients are waiting, and we are working relentlessly to advance our programs and technologies. If you are interested in partnering with CARsgen, please contact us at BD@carsgen.com. We look forward to working together.